

Scannell, Jack

Etheros Pharmaceuticals



Dr Jack Scannell has researched biomedical R&D productivity from financial, regulatory, and scientific perspectives, focusing on the contrast between cheaper and better scientific inputs, and the long-term decline in R&D output efficiency. He is now the CEO of Etheros Pharmaceuticals, a pre-clinical stage company that is developing new chemistries to treat neurodegenerative diseases. He is Associate of the Innogen Institute and of the Department of Science, Technology, and Innovation Studies at the University of Edinburgh. He had senior roles in drug and biotech investment at UBS and at Sanford Bernstein. He was Head of Discovery Research at e-Therapeutics PLC, an Oxford-based biotechnology firm. Jack was as an academic biomedical researcher through the 1990s, focusing on neuroscience. He has a PhD in Physiology from Oxford University and a degree in Medical Sciences from Cambridge University.